How mature TLSs identify solid tumor patients more likely to benefit from PD-1 blockade
How plasma LIF predicts immune-checkpoint blockade resistance and a TLS-poor tumor microenvironment
Can CD163 macrophages help select MSS colorectal cancer patients for regorafenib plus avelumab?
Quantitative histology to characterize immune contexture in human lung adenocarcinoma samples
The tumor microenvironment plays a central role in cancer progression and response to immunotherapy. Immune checkpoint inhibitors targeting the PD-1/PD-L1 axis and CTLA-4 have demonstrated major clinical benefit across several cancer indications, highlighting the importance of the tumor immune landscape in shaping therapeutic response. However, response to immune checkpoint blockade remains heterogeneous and depends on […]
Why IDO1 blockade lowered kynurenine but failed to improve anti-PDL1 efficacy in sarcoma
Does cabozantinib help in advanced Ewing sarcoma and osteosarcoma — and can plasma biomarkers flag who responds?
B Cells and Tertiary Lymphoid Structures as Key Players in Anti-Tumor Immune Response
B cells are increasingly recognized as key contributors to anti-tumor immune responses and response to cancer immunotherapy. Recent studies have demonstrated the association between B cell-enriched immune signatures and response to immunotherapy across several cancer indications, including melanoma, renal cell carcinoma, and sarcoma. In responding patients, B cells are frequently enriched within organized lymphoid aggregates […]
Why PD-1 blockade falls short in soft-tissue sarcoma — and the macrophage/IDO1 axis behind it
Why IDO1 staining can miss L-kynurenine production in colorectal and breast tumors
